NEUROSIVIR, NCT04480333: Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 |
|
|
| Recruiting | 1 | 45 | US | Drug: NA-831 - 0.10 mg/kg, NA-831 is a neuroprotective and neurogenesis drug, Placebo- 0.10 mg/kg, Placebo Comparator, Drug: NA-831 - 0.20 mg/kg, NA-81 is a neuroprotective drug, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, GS-5734 (Remdesivir) is an antiviral drug, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, GS-5734 (Remdesivir) is an anti-viral drug, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Combination therapy of NA-831 a neuroprotective drug and GS-5734 an antiviral drug, Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Combination therapy of NA-831, a neuroprotective drug and GS-5734, an antiviral drug, Placebo 0.20 mg + 2.00 mg/kg | NeuroActiva, Inc. | Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response | 12/20 | 03/21 | | |
